Quetiapine extended release for depression in young people with bipolarity
Researchers compared Quetiapine XR and placebo, tracking side effects to assess safety in children with bipolarity during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared Quetiapine XR and placebo, tracking side effects to assess safety in children with bipolarity during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Dothan and 47 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 193
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Colombia, India, ...
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00811473
- Official title
Show the full official title
An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Dothan, United States · Scottsdale, United States · Little Rock, United States
45 more locations
- Escondido, United States
- Bradenton, United States
- Gainsville, United States
- North Miami, United States
- Tampa, United States
- Atlanta, United States
- Smyrna, United States
- Eagle, United States
- Hoffman Estates, United States
- Terre Haute, United States
- Overland Park, United States
- Wichita, United States
- Clinton Township, United States
- Minneapolis, United States
- Flowood, United States
- St Louis, United States
- Lincoln, United States
- Rochester, United States
- Cincinnati, United States
- Cleveland, United States
- Mason, United States
- Oklahoma City, United States
- Charleston, United States
- Memphis, United States
- Wharton, United States
- Virginia Beach, United States
- Bothell, United States
- Milwaukee, United States
- Bogota D.c, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Medellín, Colombia
- Vijaywada, India
- Ahmedabad, India
- Vadodara, India
- Varanasi, India
- León, Mexico
- Monterrey, Mexico
- Belgrade, Serbia
- Novi Sad, Serbia
- Pretoria, South Africa
- Cape Town, South Africa
- Taoyuan, Taiwan
- Changhua, Taiwan
- Taipei, Taiwan
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Quetiapine XR and placebo, tracking side effects to assess safety in children with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine XR and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
